Drugs / Verducatib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07531628 | Jun → Aug 2026 overdue | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verducatib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07531628 ↗ |
| Route | Oral | “Multiple Oral Doses of Verducatib for 4 Weeks” NCT07531628 ↗ |